Diffuse Large B-cell-lymphoma
Conditions
Brief summary
The antibody drug conjugate (ADC) brentuximab vedotin (BV), targeting CD30, is currently registered for the treatment of previously untreated stage III-IV Hodgkin lymphoma (HL), relapsed Hodgkin lymphoma, relapsed systemic anaplastic large T-cell lymphoma (sALCL) and relapsed CD30 expressing cutaneous T-cell lymphoma, type mycosis fungoides (CTCL, MF) with overall response rates (ORR) up to 70%. BV has shown promising results in other CD30 expressing non-hodgkin lymphoma (NHL), including relapsed angio-immunoblastic T-cell lymphoma (AITL), peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), post-transplant lymphoproliferative diseases (PTLD) and diffuse large B-cell lymphoma (DLBCL) with ORR rates of 50%, 40% and 45%, respectively. Despite expression of CD30 on tumor cells, no objective responses were observed in relapsed primary mediastinal B-cell lymphoma (PMBCL). Strikingly, thus far correlative studies have not found predictive markers in tissue or blood that are predictive for response to treatment. Since CD30 expression in tumor tissue is unrelated to treatment outcome, this suggests involvement of phenomena like tumor heterogeneity, drug uptake in the tumor micro-environment or very low CD30 expression below the immunohistochemistry (IHC) threshold. In this imaging study the biodistribution of brentuximab will be investigated by using Zirconium-89 (89Zr)-labeled brentuximab. 89Zr-brentuximab imaging will help to assess tumor uptake and pharmacokinetic (PK) and -dynamic properties of brentuximab in patients who are intended to be treated with BV, either in one of the registered indications (HL, CTCL and sALCL) or as part of the HOVON 136 trial for patients with DLBCL. The hypothesize is that the results of this imaging study might be used to facilitate the identification of patients that would benefit most from BV treatment
Interventions
DRUGBrentuximab vedotin
5 Participants will receive unlabeled brentuximab and 20 participants will receive 89ZR-Brentuximab.
Sponsors
Takeda
University Medical Center Groningen
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* All patients with histologically proven CD30-positive (i.e. \> 1% cells) lymphomas who will be treated with BV, including: * HL * T-NHL * CTCL * DLBCL * Age ≥18 years * Signed written informed consent form (approved by the Institutional Review Board \[IRB\]/ Independent Ethics Committee \[IEC\]) obtained prior to any study specific screening procedures * Measurable disease: on CT scan at least 1 lesion/node with a long axis of \> 1.5 cm and at least one positive lesion on 18F-FDG PET scan * World Health Organization (WHO) performance status 0-2 (see appendix A) * Adequate hepatic function: total bilirubin ≤ 1.5 times upper limit of normal (ULN) (unless due to lymphoma involvement of the liver or a known history of Gilbert's syndrome as defined by \> 80% unconjugated bilirubin) and Alanine Aminotransferase (ALAT) / Aspartate Aminotransferase (ASAT) ≤ 3 times ULN (unless due to lymphoma involvement of the liver; in that case ALAT/ASAT may be elevated up to 5 times ULN) * Adequate renal function: GFR \> 50 milliliter/ minute (ml/min) as estimated by the cockcroft & gault formula at rehydration: Creatinine Clearance (CrCL) = (140-age \[in years\] x weight \[kg\] (x 0.85 for females) (0.815 x serum creatinine \[μmol/L\]) * Adequate bone marrow function: Absolute neutrophil count (ANC) ≥ 1.5 x 109/liter (L) and platelet count ≥100 x 109/L, unless caused by diffuse bone marrow infiltration by lymphoma * Hemoglobin must be ≥ 8 g/dL (5.0 mmol/L), transfusion is allowed * Life expectancy of \>3 months with treatment * Negative pregnancy test at study entry, if applicable
Exclusion criteria
* Prior allergic reaction or known hypersensitivity to immunoglobulins, recombinant proteins, murine proteins, or to any excipient contained in the dug formulation of BV. * Peripheral sensory or motor neuropathy grade ≥ 2 * Patients with a serious psychiatric disorder that could, in the investigator's opinion, potentially interfere with the completion of treatment according to protocol * Patients who have any severe and/or uncontrolled medical condition or other conditions that could affect their participation in the study * Any psychological, familial, sociological and geographical condition potentially hampering compliance with the study protocol and follow-up schedule * Claustrophobia to the extent that PET-CT is impossible * Pregnant or lactating women. Documentation of a negative pregnancy test must be available for pre-menopausal women with intact reproductive organs and for women less than two years after menopause
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| An optimized 89Zr-brentuximab imaging protocol for visualisation of CD30 distribution by PET-scan | 2 years | 89Zr-brentuximab imaging protocol, including the dose of brentuximab (mg), the dose of 89Zr-brentuximab (mg) and the time (day) of PET-scanning after 89Zr-brentuximab administration |
| Safety profile of the 89Zr-brentuximab tracer | 2 years | AE related to imaging protocol with the 89Zr-brentuximab tracer |
| Relation 89Zr-brentuximab biodistribution and CD30 expression | 2 years | Relation between 89Zr-brentuximab tracer uptake and CD30 protein expression |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Relation between 89Zr-brentuximab uptake and response to therapy | 2 years | The extent of heterogeneity in 89Zr-brentuximab uptake and the potential correlation with response to therapy (as determined via 18F-FDG PET/CT scan per the International Working Group criteria (1,2). |
Contacts
Primary ContactMarijn de Vries
Backup ContactImke Kraai-Nomden
Outcome results
None listed